Lili Wang#, Jiuju Zhou, Li Zhang


Department of Pediatrics, Cangzhou People’s Hospital, Cangzhou, PR China


Objective: We sought to analyse changes in bone mineral density, bone metabolism, serum insulin-like growth factor-1 (IGF-1), neuron-specific enolase (NSE) and high mobility group box 1 (HMGB1) levels in children with epilepsy and the effects of antiepileptic drugs on it to provide a clinical reference for improving the quality of life of these patients. 

Methods: Fifty children with epilepsy admitted to our hospital were selected as the observation group, while another 30 healthy children were selected as the control group. Differences in levels of bone mineral density; bone metabolism [e.g., NP and alkaline phosphatase (ALP) as markers of bone formation, blood Ca2+, blood P5+, and collagen-specific sequence CTx]; and serum IGF-1, NSE, and HMGB1 were analysed and recorded. The children in the observation group were given antiepileptic drugs for three months and changes in biochemical indicators before and after treatment were recorded. 

Results: Cases of bone abnormality in children with epilepsy were significantly higher in number than those among healthy children, and this difference was statistically significant (P<0.05). Further, bone condition had improved only to a limited degree after three months of treatment (P>0.05). The levels of type I procollagen amino-terminal propeptide (PINP) and ALP as markers of bone formation in children with epilepsy were lower than those in the normal control group, and the differences in this regard were statistically significant (P<0.05). Separately, the PINP and ALP levels as markers of bone metabolism were significantly lower than those before treatment, and the difference here was statistically significant (P<0.05). However, serum phosphorus levels were significantly lower than prior to treatment, with a difference that was statistically significant (P<0.05). Finally, the levels of IGF-1, NSE, and HMGB1 among children with epilepsy were significantly higher than those in healthy children before treatment, and the difference was statistically significant (P<0.01). However, after treatment, the above indicators were significantly decreased among children with epilepsy, and the difference was statistically significant (P<0.05). 

Conclusion: There are obvious abnormalities in bone mineral density, bone metabolism, and serum IGF-1, NSE and HMGB1 levels in children with epilepsy. The antiepileptic drug sodium valproate can effectively improve the condition of children with epilepsy, but it may affect bone metabolism.


Epilepsy, antiepileptic drug, bone metabolism, NSE, IGF-1, HMGB1.